EZH2 as an Actionable Therapeutic Target to Enhance Anti Tumor Immune Response In Prostate Cancer

Presented By: Leigh Ellis, Ph.D.

Speaker Biography: Dr. Leigh Ellis is the clinical director of the Center for Urologic Research Excellence at Cedars-Sinai Cancer and Acting Associate Professor of Medicine in the Division of Medical Oncology, Department of Medicine and Biomedical Sciences at Cedars-Sinai Medical. The Ellis laboratory concentrates on dissecting underlying genetic/epigenetic systems of aggressive prostate cancer. Our general objective is to determine unique genomic/epigenomic systems which will cause discovery of biomarkers and healing targets for scientific screening, with a particular concentrate on growth and immune cell family tree plasticity in prostate cancer driven by the loss of the growth suppressor protein, retinoblastoma-1 (RB) and partnership with the histone customizing enzyme enhancer of zeste homolog-2 (EZH2).

Webinar: EZH2 as an Actionable Therapeutic Target to Enhance Anti-Tumor Immune Response In Prostate Cancer

Webinar Abstract: Prostate cancers are thought about immunologically ‘cold’ growths provided the really couple of clients who react to checkpoint inhibitor treatment (CPI). Just recently, enrichment of interferon promoted genes (ISGs) anticipates a beneficial reaction to CPI throughout different illness websites. The enhancer of zeste homolog-2 (EZH2) is over-expressed in prostate cancer and is understood to adversely manage ISGs. Here, we show that EZH2 inhibition in prostate cancer designs triggers a dsRNA-STING-ISG tension action upregulating genes associated with antigen discussion, Th-1 chemokine signaling, and interferon (IFN) reaction, consisting of PD-L1 that depends on STING activation.

Make PACE Credits:
1. Ensure you’re a signed up member of LabRoots https://www.labroots.com/virtual-event/immuno-oncology-2021/ program
2. See the webinar on YouTube or on the LabRoots Website https://www.labroots.com/webinar/ezh2-actionable-therapeutic-target-enhance-anti-tumor-immune-response-prostate-cancer
3. Click on this link to get your PACE credits (Expiration date– June 02, 2023 ): https://www.labroots.com/credit/pace-credits/6165/ third-party

LabRoots on Social:
Facebook: https://www.facebook.com/LabRootsInc
Twitter: https://twitter.com/LabRoots
LinkedIn: https://www.linkedin.com/company/labroots
Instagram: https://www.instagram.com/labrootsinc
Pinterest: https://www.pinterest.com/labroots/
SnapChat: labroots_inc.

http://medicaltranscriptionprograms.com/ezh2-as-an-actionable-therapeutic-target-to-enhance-anti-tumor-immune-response-in-prostate-cancer/